Gene Delivery Particles to Induce Tumor-Derived Antigen Presenting Cells
Generated by an autonomous AI research agent — Anthropic Claude Opus 4.7 or OpenAI GPT-5.5, max reasoning effort. Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
Metastatic melanoma
Modality
Gene Therapy
Mechanism
Gene delivery particles inducing tumor-derived antigen-presenting cells
Target
—
rNPV Envelope
Low
-$54.0M
costs +25% · peak −25%
Base
-$41.9M
cumulative PoS 1.5%
High
-$29.9M
costs −25% · peak +25%
Costs follow the cell/gene-therapy band adjusted downward for a non-viral polymeric nanoparticle (no viral-vector GMP burden) and a small intralesional melanoma trial footprint, anchored to the T-VEC/RP1 intratumoral-immunotherapy development path. PoS is deliberately depressed below generic gene-therapy benchmarks: the Phase 2 value (0.22) reflects that the three most mechanism-true clinical analogs — TAVO-EP (failed KEYNOTE-695 Phase 2b), SAR441000/BNT131 (discontinued), mRNA-2752 (discontinued) — all failed at or before efficacy proof, and Phase 3 (0.38) reflects T-VEC's modest single-agent benefit and RP1's FDA single-arm-evidence setback. Cumulative LoA = 0.40×0.55×0.22×0.38×0.80 ≈ 1.5%, appropriately bleak for a preclinical asset in a graveyard class.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.60
Modality fit · 30%
0.74
Whitespace · 30%
0.50
Composite 0.612 — composite-score rank #25 of 50 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#34) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
Tavokinogene telseplasmid / TAVO-EP (OncoSec Medical) — intratumoral plasmid IL-12 + electroporation
CAUTIONARY PRECEDENT, status-flagged: the single most mechanism-true clinical analog — non-viral intratumoral DNA delivery of an immunostimulatory cytokine (IL-12) to reprogram the melanoma microenvironment and drive a systemic anti-tumor T-cell response (Greaney/Algazi/Daud 2019 showed exactly the abscopal effect this asset targets). It failed the registration-directed KEYNOTE-695 Phase 2b with confirmed ORR 10.2% (below the pre-specified bar) and OncoSec filed Chapter 7 bankruptcy in June 2023. It is NOT a live anchor — it is the clearest demonstration of the clinical and commercial risk this asset class carries.
Criteria 1 and 2: same mechanism class (non-viral intratumoral immune-gene delivery, IL-12 payload, in situ TME reprogramming) and same indication (metastatic melanoma). Cautionary status precedent only — program discontinued, sponsor bankrupt.
Talimogene laherparepvec / Imlygic / T-VEC (Amgen) — intratumoral oncolytic immunotherapy
Regulatory and commercial anchor: the FIRST and (through 2025) essentially only FDA-approved intratumoral immunotherapy in melanoma (2015, pivotal OPTiM Phase 3, Andtbacka 2015). It establishes the regulatory pathway and endpoint precedent (durable response rate; intralesional immunotherapy accepted by FDA/CBER) AND the sobering commercial ceiling — US peak sales only reached roughly $100M. Mechanistically adjacent (intratumoral in situ immune activation in melanoma) though delivered by an engineered oncolytic HSV-1, not a polymeric gene-delivery nanoparticle.
Criteria 2 and 3: same indication and same regulatory pathway (FDA-approved intralesional immunotherapy for melanoma); anchors the realistic commercial ceiling of the approved intratumoral-immunotherapy category.
Vusolimogene oderparepvec / RP1 (Replimune) — intratumoral oncolytic immunotherapy + nivolumab
Most-current ACTIVE adjacent program: intratumoral immune-activating biologic in anti-PD-1-refractory advanced melanoma (IGNYTE, NCT03767348). Status as of 2026: FDA issued a Complete Response Letter in July 2025 (FDA judged the single-arm IGNYTE trial not adequate and well-controlled), Replimune resubmitted the BLA, which FDA accepted in October 2025 with a PDUFA date of April 10, 2026. Live but unapproved — a cautionary regulatory datapoint for any intratumoral immunotherapy relying on single-arm registration evidence.
Criteria 2 and 3: same indication (PD-1-refractory melanoma) and same regulatory pathway (intratumoral immunotherapy BLA); active program anchoring current FDA expectations and the single-arm-evidence regulatory risk.
SAR441000 / BNT131 (Sanofi / BioNTech) — intratumoral mRNA mixture (IL-12sc, IL-15sushi, IFNα2b, GM-CSF)
CAUTIONARY PRECEDENT, status-flagged: the closest payload-concept analog — intratumoral delivery of a multi-gene cytokine cassette (IL-12 + IL-15 among them, the same cytokines this JHU asset's broader claim set lists) to inflame the TME, ± anti-PD-1. Sanofi and BioNTech jointly discontinued the program (~2023) after an interim analysis of early-phase data. Not a live anchor; reframed as evidence that even big-pharma-resourced intratumoral cytokine cocktails have repeatedly failed to clear the efficacy bar.
Criteria 1: same mechanism class (non-viral intratumoral immune-gene delivery, overlapping IL-12/IL-15 cytokine payload, in situ TME reprogramming). Cautionary status precedent only — program discontinued.
mRNA-2752 (Moderna) — intratumoral LNP mRNA (OX40L / IL-23 / IL-36γ)
CAUTIONARY PRECEDENT, status-flagged: nanoparticle-delivered intratumoral mRNA co-encoding a T-cell costimulator (OX40L) and pro-inflammatory cytokines, ± durvalumab, with melanoma expansion cohorts — conceptually the nearest non-viral nanoparticle co-stim+cytokine analog. Moderna discontinued mRNA-2752 in 2024 as part of pipeline prioritization. Not a live anchor; reframed as the third independent discontinuation in the intratumoral co-stim/cytokine gene-delivery class.
Criteria 1: same mechanism class (non-viral nanoparticle intratumoral delivery of costimulatory + cytokine genes for in situ immune reprogramming). Cautionary status precedent only — program discontinued.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $22.0M | 30 mo | 40.0% | [0] [1] |
| Phase I | $45.0M | 18 mo | 55.0% | [1] [2] |
| Phase II | $110.0M | 30 mo | 22.0% | [2] [3] [4] |
| Phase III | $230.0M | 40 mo | 38.0% | [3] [5] |
| NDA/BLA Review | $16.0M | 12 mo | 80.0% | [5] |
Multiplier handling: Eligible multipliers (expedited_pathway_melanoma_immunotherapy) are already reflected in Day-1 comparator-calibrated PoS. Re-applying them via log-odds stacking would double-count, so per-stage PoS is taken as final. See methodology for the rule.
Peak revenue and discount rate
$250.0M peak · WACC 15.0%
Peak revenue. The only approved comparator in this exact niche, T-VEC/Imlygic, reached just ~$100M US peak despite first-mover status and Amgen's commercial muscle — intralesional administration, restriction to accessible lesions, and competition from systemic checkpoint inhibitors structurally cap the category. A successful, differentiated in situ reprogramming agent used as a checkpoint-combination in PD-1-refractory melanoma could plausibly exceed T-VEC on global pricing and broader lesion eligibility, but a ~$250M risk-adjusted peak is the defensible ceiling for a single-indication intratumoral immunotherapy; this is an envelope for cohort consistency, not a standalone-equity revenue thesis (see archetype).
WACC. A preclinical non-viral gene-delivery immunotherapy whose three nearest clinical analogs all failed or were discontinued and whose approved category anchor commercially underperformed warrants a high discount rate above the gene-therapy norm.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$41.9M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$119.4M
P25
-$52.3M
P50 (median)
-$23.6M
P75
-$13.5M
P95
-$7.3M
Prob ≥ 0
1.3%
Comparable launch curves
Revenue trajectories of named comparators
Talimogene laherparepvec / Imlygic / T-VEC (Amgen) — intratumoral oncolytic immunotherapy
Launched 2015 · peak $95.0M (estimated)
Evidence register
8 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
Core mechanism and preclinical-only stage (PBAE nanoparticle delivering 4-1BBL + IL-12 plasmid DNA reprogramming melanoma cells into tumor-associated APCs in situ) stage_profile.preclinical.pos | In situ genetic engineering of tumors for long-lasting and systemic immunotherapy (Tzeng et al.) peer_review | 2020-02-04 | high |
JHTV listing: synthetic PBAE nanoparticle gene delivery, in vivo mouse + in vitro data only, two pending PCT applications stage_profile.preclinical.duration_months | JHTV Technology 35363 — Gene Delivery Particles to Induce Tumor-Derived Antigen Presenting Cells company_filing | 2021-01-01 | high |
Mechanism-true clinical precedent: intratumoral plasmid IL-12 induces systemic anti-tumor T-cell responses in melanoma (TAVO/OncoSec proof-of-concept) stage_profile.phase_1.pos | Intratumoral plasmid IL-12 electroporation therapy in advanced melanoma patients induces systemic and intratumoral T cell responses (Greaney, Algazi, Daud, Fong) trial_disclosure | 2019-12-18 | high |
Cautionary class precedent: registration-directed Phase 2b of the nearest clinical analog (TAVO-EP + pembrolizumab) in metastatic melanoma stage_profile.phase_2.pos | KEYNOTE-695 Phase 2b registration-directed clinical trial of TAVO-EP in combination with pembrolizumab in metastatic melanoma (NCT03132675) trial_disclosure | 2022-11-01 | medium |
Earlier-stage TAVO melanoma program (in-transit cutaneous melanoma) anchoring intralesional immune-response endpoints stage_profile.phase_2.duration_months | Tavokinogene Telseplasmid (tavo) and OncoSec Medical System in Melanoma (NCT01502293) trial_disclosure | 2015-06-01 | medium |
Regulatory + commercial anchor: T-VEC/Imlygic, first FDA-approved intratumoral immunotherapy for melanoma, modest commercial ceiling peak_revenue_usd | Imlygic (talimogene laherparepvec) — FDA Cellular & Gene Therapy Products regulatory | 2015-10-27 | high |
Pivotal Phase 3 endpoint precedent for intratumoral melanoma immunotherapy (OPTiM, T-VEC durable response rate) stage_profile.phase_3.pos | Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma (Andtbacka et al., OPTiM, J Clin Oncol) trial_disclosure | 2015-09-01 | high |
Current FDA expectations / single-arm-evidence regulatory risk for intratumoral melanoma immunotherapy (RP1 IGNYTE) wacc_suggestion | IGNYTE: RP1 (vusolimogene oderparepvec) + nivolumab in advanced solid tumors / melanoma (NCT03767348) trial_disclosure | 2025-10-01 | medium |
Thesis
Why this asset earns its rank
This is a genuine but very early therapeutic concept, not a research reagent: a non-viral poly(beta-amino ester) (PBAE) nanoparticle that transfects melanoma cells in situ with plasmid DNA encoding a costimulatory ligand and an immunostimulatory cytokine (4-1BBL + IL-12 in the foundational Tzeng et al. PNAS 2020 work; the broader claim set lists CD80/CD86/OX40L and IL-2/IL-12/IL-15). Tumor cells already present antigen (signal 1); supplying signals 2 and 3 converts them into antigen-agnostic 'tumor-associated APCs' that prime a systemic, durable anti-tumor T-cell response, demonstrated as B16-F10 tumor control and occasional clearance with checkpoint blockade. Mechanistically the insight is sound and the in situ approach elegantly sidesteps neoantigen identification. The pinned rubric bucket is gene_therapy and that is correct in kind, but a CMO should note this is a non-viral, transiently-transfecting polymeric nanoparticle — its durability, redosing, and CMC profile differ materially from viral-vector gene therapy, and the asset is preclinical (mouse + in vitro only, two pending PCT applications, no IND).
The economic frame is dominated by an unusually unfavorable comparator landscape. The single most mechanism-true clinical analog, OncoSec's intratumoral plasmid IL-12 (TAVO-EP), proved the exact biology (Greaney/Algazi/Daud 2019: systemic T-cell responses from local DNA delivery) yet failed the registration-directed KEYNOTE-695 Phase 2b (confirmed ORR 10.2%) and the sponsor entered Chapter 7 bankruptcy; the two nearest payload analogs, Sanofi/BioNTech SAR441000 (IL-12/IL-15/IFN/GM-CSF) and Moderna mRNA-2752 (OX40L/IL-23/IL-36γ), were both discontinued. The only FDA-approved intratumoral melanoma immunotherapy, T-VEC/Imlygic, validates the regulatory path but peaked at only ~$100M US, and the most current active analog, Replimune's RP1, drew an FDA Complete Response Letter on single-arm evidence (PDUFA April 10, 2026). The engine result is -$54.0M to -$29.9M, with a base rNPV of -$41.9M and cumulative PoS of 1.5%; that spread should be read as a cohort-consistency illustration, not a standalone-equity case — the comparator graveyard, not the model, is the decision driver.
Verdict: scientifically credible, commercially and clinically high-risk, and best pursued via a strategic immuno-oncology partner or platform license rather than standalone venture equity — hence the partnership_candidate archetype. It earns its rank 23 on the rubric's high modality_pos (gene-therapy bucket) and strong IRA-exposure subscore plus mid clinical-relevance for an explicitly stated aggressive-melanoma indication, not on a de-risked product economic case; the rank reflects modality and indication salience, which is exactly what the rubric measures.
Key risks
Asset-specific, not generic biotech risks
- Class graveyard: the three most mechanism-true clinical programs — TAVO-EP (failed KEYNOTE-695 Phase 2b, sponsor bankrupt), SAR441000/BNT131 (discontinued), mRNA-2752 (discontinued) — all failed at or before efficacy proof. Local cytokine/costimulatory immune-gene delivery has repeatedly produced strong immunologic biomarkers but not registrational ORR/survival benefit; this asset must explain why a polymeric-nanoparticle delivery format breaks that pattern.
- Modality-bucket vs reality: pinned as gene_therapy but mechanistically a non-viral, transiently-transfecting PBAE polymer nanoparticle. Transfection efficiency, expression durability, repeat-dosing, intratumoral biodistribution in human (vs murine B16) tumors, and polymer CMC/immunogenicity are unproven and are not captured by viral-vector gene-therapy benchmarks.
- Commercial ceiling: the only approved comparator (T-VEC) peaked near ~$100M US despite first-mover status; intralesional administration limits addressable lesions and competes against systemic checkpoint inhibitors. A standalone single-indication intratumoral immunotherapy has a structurally capped peak — the economics support a partnership/license, not venture equity.
- Regulatory evidence bar: RP1's FDA Complete Response Letter (single-arm IGNYTE deemed not adequate and well-controlled) signals that intratumoral melanoma immunotherapies will likely need randomized, controlled registrational data — raising Phase 3 cost, duration, and risk well above a single-arm accelerated assumption.
- Preclinical-only and IP-early: efficacy is mouse B16-F10 + in vitro only with two pending (not granted) PCT applications and no IND; antigen-agnostic in situ reprogramming has not been shown to translate from immunogenic murine models to typically less inflamed human metastatic melanoma.